In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Spyre Therapeutics Inc (NASDAQ: SYRE) closed at $22.39 in the last session, down -2.01% from day before closing price of $22.85. In other words, the price has decreased by -$2.01 from its previous closing price. On the day, 0.5 million shares were traded. SYRE stock price reached its highest trading level at $22.985 during the session, while it also had its lowest trading level at $21.88.
Ratios:
We take a closer look at SYRE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.90 and its Current Ratio is at 10.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on September 26, 2025, initiated with a Buy rating and assigned the stock a target price of $43.
On April 08, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $45.
On March 18, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $27.Wolfe Research initiated its Outperform rating on March 18, 2025, with a $27 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Turtle Cameron sold 45,000 shares for $23.33 per share. The transaction valued at 1,049,778 led to the insider holds 701,907 shares of the business.
CAMERON TURTLE bought 90,000 shares of SYRE for $2,201,400 on Nov 03 ’25. On Sep 02 ’25, another insider, Burrows Scott L, who serves as the Chief Financial Officer of the company, sold 18,428 shares for $16.26 each. As a result, the insider received 299,639 and left with 97,994 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 1737287680 and an Enterprise Value of 1406909824.
Stock Price History:
The Beta on a monthly basis for SYRE is 3.17, which has changed by -0.4226153 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $40.26, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is 18.53%, while the 200-Day Moving Average is calculated to be 28.28%.
Shares Statistics:
According to the various share statistics, SYRE traded on average about 819.11K shares per day over the past 3-months and 820210 shares per day over the past 10 days. A total of 77.50M shares are outstanding, with a floating share count of 68.39M. Insiders hold about 11.75% of the company’s shares, while institutions hold 77.58% stake in the company. Shares short for SYRE as of 1760486400 were 13390470 with a Short Ratio of 16.35, compared to 1757894400 on 13780763. Therefore, it implies a Short% of Shares Outstanding of 13390470 and a Short% of Float of 20.879998999999998.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Spyre Therapeutics Inc (SYRE) in the stock market.The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.49 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$1.88 and -$2.31 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$2.88, with 10.0 analysts recommending between -$1.92 and -$4.2.
